When: Confirmed daily close above $101.79 (50 SMA) on expanding volume with MACD histogram turning positive

Then: Upgrade to Hold

When: Daily close below $89.50 (lower Bollinger) on rising volume

Then: Exit residual equity position

When: Daily close below $84.50 (200 SMA) on volume

Then: Full exit of residual — confirms structural break, downgrade to Sell

SELL (trim 45-50% of position)

• Agrees with aggressive analyst on regime change, broken divergence, four-layer resistance stack, and asymmetric downside
• Disagrees with aggressive analyst on execution—should not trim to 60-70%, must stay within trader's 30-50% guidance
• 200 SMA ($0? price $8 above it) is the long-term bull trend line; structural uptrend intact until tested and failed on confirmed close
• PEG of 0.25 is not a value signal—market is pricing in skepticism about $851 consensus EPS estimate
• Q3 medical loss ratio is a proof point, but multiple macro risks exist before Q3: 86% Polymarket-implied probability of no rate cuts, rising ten-year yields, Hormuz-driven oil spike pulling risk-off bid, Walmart prescription miss indicating pharmacy economics under pressure
• Q2 40% EPS beat, raised AOI twice, $20B tech push, Heitsenrether board add—most of this is already in the price (stock ran from $69.51 to over $110)
• 400 SMA range between current price and 200 SMA
• Stop at $92.50
• If price closes below $88.19 on volume, cut the rest (lower band test in play)
• If price reclaims 10 EMA at $95.66 with RSI above 45, keep residual position (long-term trend intact)
• Negative tangible book value, 95% debt to equity, structural impairment disclosed by management
• RSI at 35 indicates oversold condition; if CVS bounces off oversold RSI 35 with Bollinger lower band test, trimming too aggressively leaves no exposure to snap-back

→ vs aggressive: Leaning to 60-70% trim exceeds trader's guidance ceiling and leaves no exposure if the bounce off the 200 SMA materializes—you'll be forced to chase into strength

→ vs aggressive: Treating 200 SMA as a non-event is incorrect; price is still $8 above it and the structural uptrend is intact until that level is tested and fails on a confirmed close

→ vs aggressive: Aggressive SELL on value trap is a directional conviction call, not risk management—if medical cost trend normalizes favorably in Q3 and $851 EPS prints, short gets steamrolled on a short into rising resistance turned support

→ vs neutral: HOLD with no defined exit is a recipe for sitting through a 9-15% drawdown while waiting for a catalyst that may not resolve the way expected

→ vs neutral: Accumulate on weakness without defined size, defined stop, and defined re-underwriting point is not a strategy—it's hope and averaging into a position with negative tangible book value and 95% debt to equity

→ vs neutral: Constructive fundamentals (Q2 40% EPS beat, raised AOI twice, $20B tech push, Heitsenrether board add) are mostly in the price after the prior run from $69.51 to over $110; the market is now asking for proof at a lower price

→ vs neutral: Ignoring macro risks (no rate cuts, rising yields, oil spike, pharmacy pressure) while waiting for Q3 micro catalyst is dangerous—each is a real, tradable risk independent of Aetna margins

BUY (maintain residual position with defined re-underwriting rules)

• Trim approximately 40% now (midpoint of 30-50% range), with option to push to 50% on confirmed close below 93.01 on volume
• 200 SMA at 84.64 represents 8 dollars of structural distance from current price; cannot declare trend dead without testing it
• Stop at 92.50 is approximately three quarters of one ATR from August 20 close of 93.65—essentially the noise band that will get triggered by single intraday wick
• Structural break trigger is confirmed close below 88.19 (lower Bollinger band) on above-average volume—not the 92.50 noise stop
• Hold residual position if price reclaims 95.66 with RSI back above 45 on daily close; do not add
• Redeploy portion of trim into hedge or pair trade benefiting from weakness in MA-exposed or PBM-exposed names without CVS-specific risk
• PEG of 0.25 with consensus 8.51 EPS is heroic but represents potential value trap if medical cost trend normalizes favorably in Q3
• Macro is mixed: Polymarket pricing 86 percent no cuts, but US recession by end of 2026 only 8 percent (soft-landing base case)
• Dividend yield at 2.84 percent provides meaningful total return contribution not contingent on price action
• FCF of 8.1 billion TTM funding deleveraging: debt down from 82.7 to 76.3 billion in four quarters, net debt down 4.6 billion from peak
• Q3 medical loss ratio print is the defined catalyst the residual position is sized to survive either direction

→ vs aggressive: Over-aggressive trim beyond trader's 30-50% guidance substitutes conviction for discipline; 70% trim risks forced chasing on a 5% bounce off lower Bollinger band

→ vs aggressive: Dismissed 200 SMA at 84.64 (8 dollars structural distance) without testing it—cannot declare trend dead on correction that hasn't reached the trend line

→ vs aggressive: PEG of 0.25 leap to structural downgrade bet is directional conviction dressed as risk management; no defined exit if 8.51 EPS prints closer to reality

→ vs conservative: 200 SMA as safety net accepts 9.5 percent drawdown before acting—the point of trimming now is to reduce exposure while trimming is optional, not forced

→ vs conservative: Stop at 92.50 is approximately three quarters of one ATR from August 20 close of 93.65; anchored framework to noise band that gets triggered at worst moment (mid-gap, session preceding snap-back)

→ vs conservative: 'Let the market tell you' is deferring every decision until price forces it—same as aggressive analyst with different vocabulary; neither builds defined re-underwriting rule that says 'if X happens, I do Y'

→ vs conservative: Both analysts omitted gap risk and single-name concentration from their frameworks

→ vs conservative: Both analysts selectively used bearish macro inputs while ignoring constructive ones (soft-landing base case, CVS Caremark scale advantage at next contract renewal, Q3 catalyst)